secwatch.observer — SEC 8-K summary
======================================

Issuer:     Envoy Medical, Inc. (COCH)
CIK:        0001840877
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001213900-24-043601
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Envoy Medical Q1 revenue $59K, down from $78K; draws $5M from $10M Glen Taylor loan
--------------------------------------------------------------------------------

- Revenue $59K for Q1 2024 vs $78K in Q1 2023; decrease due to fewer battery replacement requests.
- R&D expense increased $0.4M; G&A expense increased $0.7M; sales/marketing down $46K.
- Cash and cash equivalents $4.9M as of March 31, 2024.
- Entered $10M unsecured loan facility with Glen Taylor; initial draw $5M at 8% interest, five-year term.
- All three EFS participants at Mayo completed 12-month follow-up; plan to file IDE for Acclaim CI pivotal trial later in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840877/000121390024043601/0001213900-24-043601-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840877/000121390024043601/ea0206113-8k_envoymed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-043601

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer